Oncology ESMO25: The changing landscape of rare oncology, with Jan Ki... ESMO sees many presentations on cancers of the lung, breast, and bladder - for example - but this year there was meaningful data in rare cancers, too.
News RevMed hails first-line data with pancreatic cancer drug Revolution Medicine's fast-growing pan-RAS inhibitor Rasonque has generated exciting results as a first-line treatment for pancreatic cancer.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.